Skip to main content
Caplight Logo









Advamedica

Advamedica

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://advamedica.com/

Last Round

Series B

Extension

Jul 27, 2021

Total Funding Raised

$21M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Advamedica is a medical technology company that develops biomaterials-based medical devices for managing trauma, surgical, and chronic wounds.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Advanced Materials, Biotechnology

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Non-AI

Keywords

hemostatic dressingwound carebiomaterialsurgical hemostatchitosan dressingbleeding controlmedtechtrauma carebioadhesiveemergency medical suppliessurgical supplieshemostasismedical device manufacturerEMS suppliesadvanced wound management

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Advamedica Comparables

Compare Advamedica with similar companies based on industry and business-model similarity.

Advamedica comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Beeken Biomedical
86%
CELOX Medical
85%
Core Scientific Creations
83%

Advamedica Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series B ExtensionJul 27, 2021
Series B ExtensionJan 9, 2020
Series BJan 26, 2018
Series AMay 25, 2016
GrantSep 11, 2013
Seed
Dec 3, 2010

Advamedica Investors

Notable investors and investment history

Advamedica investors
InvestorRounds
GVFLSeed
Omidyar Network IndiaSeries B Extension
Department of Science & TechnologyGrant
TrueScale CapitalSeries B Extension
GVFL LimitedSeed
Chiratae VenturesSeries A, Series B Extension, Series B
RNT AssociatesSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 20, 2026

    Monthly visitors increased 52% MoM.

  • Jan 26, 2018

    $7.4M round led by RNT Associates.

Advamedica Filings

Explore SEC and related filing metadata, where available.

Advamedica filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Advamedica's valuation, stock price, and market status.

Is Advamedica a public or private company?

Advamedica is a private company.

What is the current stock price of Advamedica?

Advamedica is a private company with no public stock price. No recent secondary market data is available.

How much is Advamedica worth (valuation)?

Valuation information for Advamedica is not publicly available.

Can I buy Advamedica stock?

Advamedica shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Advamedica's last funding round?

Advamedica's most recent funding round was Series B Extension on July 27, 2021.

Who are the main investors in Advamedica?

Key investors in Advamedica include GVFL, TrueScale Capital, RNT Associates.

Will Advamedica IPO soon?

No public IPO plans have been announced for Advamedica.

How can I track Advamedica secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Advamedica's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range3
Year Founded2015
Last FundingJul 27, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?